+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatomyositis - Epidemiology Forecast - 2034- Product Image
Dermatomyositis - Epidemiology Forecast - 2034- Product Image
Sale

Dermatomyositis - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 110 Pages
  • August 2024
  • Region: Global
  • DelveInsight
  • ID: 5525737
UP TO OFF until Dec 31st 2024
Description Jump to:

Key Highlights

  • In 2023, there were approximately 29.43 million diagnosed prevalent cases of acne vulgaris in the 7MM, these cases are further expected to increase during the forecast period (2024-2034).
  • Factors contributing to the rise of diagnosed prevalent cases of acne vulgaris include hormonal changes, dietary influences, genetic predisposition, and environmental factors such as pollution.
  • The total diagnosed prevalence of acne vulgaris in the 7MM is expected to increase at a CAGR of 0.4% owing to changes in lifestyles, diet and escalated changes in the hormonal levels.
  • The Age-specific prevalent cases of acne vulgaris are divided into the following groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, a higher number of cases were observed in the age group 15-19 years compared to others, comprising around 5.85 million cases in 2023.
  • Among EU4 and the UK, Germany had the highest diagnosed prevalent population of acne vulgaris, with 3,486,784 cases, followed by France and Italy in 2023.
  • As per the analyst's estimates, Japan accounted for nearly 10% of the Total Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM in 2023.
This report delivers an in-depth understanding of Acne Vulgaris, historical and forecasted epidemiology of Acne Vulgaris in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Acne Vulgaris Disease Understanding

Acne Vulgaris Overview

Acne vulgaris is a chronic inflammatory dermatological condition characterized by pimples, blackheads, and whiteheads on the skin, primarily affecting pilosebaceous units across various age groups, with adolescents being the most commonly affected demographic. The severity of acne can be classified into mild, moderate, and severe based on the presence of non-inflammatory and inflammatory lesions, erythema, and scarring. The pathogenesis involves a multifactorial interplay of hormonal influences, sebum production, follicular hyperkeratinization, bacterial proliferation, and inflammation, exacerbated by genetic predisposition, medications, and environmental factors. Key symptoms include comedones, inflammatory lesions, and scarring. The management of acne is challenging due to various risk factors, emphasizing the need for comprehensive understanding and targeted interventions.

Acne Vulgaris Diagnosis

Diagnosis of acne vulgaris typically involves a thorough clinical examination of the skin to assess the type, severity, and distribution of lesions. In some instances, additional diagnostic procedures are employed to rule out other skin conditions or determine bacterial involvement. These procedures include skin biopsies and microbial cultures. Furthermore, additional tests such as microbial testing, hormonal evaluations, and liver function tests may be conducted in specific cases to provide a comprehensive understanding of the condition.

Acne Vulgaris Epidemiology

For the purpose of designing the patient-based model for the Acne Vulgaris epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Prevalent Cases of Acne Vulgaris, Diagnosed Prevalent Cases of Acne Vulgaris, Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris, Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris, and Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
  • In 2023, an estimated ~140,217 thousand prevalent cases of Acne Vulgaris occurred across the 7MM, with approximately 69.50 million cases attributed to the US alone. These numbers are expected to increase steadily throughout the forecast period.
  • The categorization based on gender, showed that diagnosed prevalent cases in females were higher than in males in the 7MM. The female-diagnosed prevalent cases accounted for 63% of the total cases in the 7MM.
  • The prevalent cases of acne vulgaris were sub-segmented further based on the severity of the acne as mild, moderate, and severe. In 2023, the highest diagnosed prevalent cases of acne vulgaris were reported as moderate (45%), whereas there were least cases in the severe (10%) segment in the 7MM.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Wake Forest University School of Medicine, North Carolina; Department of Dermatology and Venereology, University Clinic Hamburg-Eppendorf, Hamburg, Germany; La Roche-Posay Pharmaceutical Laboratory, France; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Acne Vulgaris, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Acne Vulgaris Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Total Prevalent Cases of Acne Vulgaris
  • Total Diagnosed Prevalent Cases of Acne Vulgaris
  • Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris
  • Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris
  • Age-specific Diagnosed Prevalent Cases of Acne Vulgaris

Acne Vulgaris Report Key Strengths

  • 11 years Forecast
  • The 7MM Coverage
  • Acne Vulgaris Epidemiology Segmentation

Acne Vulgaris Report Assessment

  • Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Acne Vulgaris? What will be the growth opportunities across the 7MM concerning the patient population of Acne Vulgaris?
  • What is the historical and forecasted Acne Vulgaris patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • Why is the diagnosed prevalent cases of Acne Vulgaris in Japan lower than the US?
  • Which country has a high patient share for Acne Vulgaris?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Acne Vulgaris prevalence cases in varying geographies over the coming years.
  • A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Acne Vulgaris, along with diagnosed prevalence of Acne Vulgaris Based on severity of airflow limitation and diagnosed prevalence of Acne Vulgaris based on symptoms and exacerbation history.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Acne Vulgaris Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Acne Vulgaris cases in 2023?

The highest cases of Acne Vulgaris was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Acne Vulgaris cases in 2023?

The highest cases of Acne Vulgaris were found in the US among the 7MM in 2023.

Table of Contents

1. Key Insights2. Report Introduction
3. Dermatomyositis Epidemiology Overview at a Glance
3.1. Patient Share Distribution of Dermatomyositis in 2020
3.2. Patient Share Distribution of Dermatomyositis in 2034
4. Epidemiology Forecast Methodology5. Executive Summary of Dermatomyositis6. Key Events
7. Disease Background and Overview
7.1. Introduction to Dermatomyositis
7.2. Types of Dermatomyositis
7.3. Signs and Symptoms
7.4. Clinical Manifestation of Dermatomyositis
7.5. Causes
7.6. Complications
7.7. Pathophysiology
7.8. Diagnosis
7.8.1. Diagnostic Criteria
7.8.1.1. Bohan and Peter's Classification Criteria for Polymyositis and Dermatomyositis
7.8.2. the Myositis Association: Diagnostic Criteria for Dermatomyositis
7.8.3. Diagnostic Criteria for Polymyositis and Dermatomyositis
7.8.4. Differential Diagnosis
7.8.5. Diagnostic Guidelines
7.8.5.1. the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Iim
7.8.5.2. Clinical Practice Guidance for Juvenile Dermatomyositis (Jdm) 2018: Japan
7.8.5.3. Single Hub and Access Point for Pediatric Rheumatology in Europe (Share): Consensus-based Recommendations for the Management of Juvenile Dermatomyositis
7.8.6. Diagnostic Algorithm
8. Patient Journey
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: 7MM
9.2.1. Total Diagnosed Prevalent Cases of Dermatomyositis
9.2.1.1. Diagnosed Prevalent Cases of Juvenile Dermatomyositis
9.2.1.2. Diagnosed Prevalent Cases of Adult Dermatomyositis
9.2.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis
9.2.3. Gender-Specific Diagnosed Prevalence of Dermatomyositis
9.2.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis
9.2.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis
9.2.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis
9.3. Total Diagnosed Prevalent Cases of Dermatomyositis in the 7MM
9.4. the United States
9.4.1. Total Diagnosed Prevalent Cases of Dermatomyositis in the US
9.4.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in the US
9.4.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in the US
9.4.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the US
9.4.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the US
9.4.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the US
9.5. EU4 and the UK
9.5.1. Germany
9.5.1.1. Total Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.1.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.1.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.1.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.1.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.1.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Germany
9.5.2. France
9.5.2.1. Total Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.2.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.2.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.2.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.2.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.2.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in France
9.5.3. Italy
9.5.3.1. Total Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.3.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.3.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.3.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.3.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.3.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Italy
9.5.4. Spain
9.5.4.1. Total Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.4.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.4.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.4.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.4.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.4.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Spain
9.5.5. the United Kingdom
9.5.5.1. Total Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.5.5.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.5.5.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.5.5.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.5.5.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.5.5.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in the UK
9.6. Japan
9.6.1. Total Diagnosed Prevalent Cases of Dermatomyositis in Japan
9.6.2. Age-Specific Diagnosed Prevalent Cases of Dermatomyositis in Japan
9.6.3. Gender-Specific Diagnosed Prevalent Cases of Dermatomyositis in Japan
9.6.4. Severity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Japan
9.6.5. Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Japan
9.6.6. Comorbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis in Japan
10. Kol Views
11. Appendix
11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of Epidemiology (2020-2034)
Table 2: Comparison of Juvenile Dermatomyositis and Adult Dermatomyositis
Table 3: Cutaneous Manifestations of Adult Dermatomyositis
Table 4: Systemic Manifestations of Dermatomyositis in Adults and Children
Table 5: Bohan and Peter Classification Criteria for Polymyositis and Dermatomyositis
Table 6: Diagnostic Criteria for Dermatomyositis
Table 7: The European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile IIM
Table 8: Currently Used ‘Guidance for Diagnosis in Specified Pediatric Chronic Diseases
Table 9: Recommendations Regarding Diagnosis
Table 10: Total Diagnosed Prevalent Cases of Dermatomyositis in the 7MM (2020-2034)
Table 11: Total Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 12: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 13: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 14: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 15: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 16: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Table 17: Total Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 18: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 19: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 20: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 21: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 22: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Table 23: Total Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 24: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 25: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 26: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 27: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 28: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Table 29: Total Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 30: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 31: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 32: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 33: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 34: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Table 35: Total Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 36: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 37: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 38: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 39: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 40: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Table 41: Total Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 42: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 43: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 44: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 45: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 46: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Table 47: Total Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 48: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 49: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 50: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 51: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 52: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Table 53: Total Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Table 54: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Table 55: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Table 56: Severity-specific Diagnosed Prevalent cases of Dermatomyositis in Japan (2020-2034)
Table 57: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Table 58: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
List of Figures
Figure 1: Signs and Symptoms of Dermatomyositis
Figure 2: Contributing Factors to Dermatomyositis
Figure 3: Causes of Dermatomyositis
Figure 4: Complications Associated With Dermatomyositis
Figure 5: The Vicious Pro-inflammatory Circle in Dermatomyositis
Figure 6: Classification Tree for a Subtype of IIM
Figure 7: Patient Journey of Dermatomyositis
Figure 8: Total Diagnosed Prevalent Cases of Dermatomyositis in the 7MM (2020-2034)
Figure 9: Total Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 10: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 11: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 13: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 14: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in the US (2020-2034)
Figure 15: Total Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 16: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 17: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 18: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 19: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 20: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in EU4 and the UK (2020-2034)
Figure 21: Total Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 22: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 23: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 24: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 25: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 26: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Germany (2020-2034)
Figure 27: Total Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 28: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 29: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 30: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 31: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 32: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in France (2020-2034)
Figure 33: Total Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 34: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 35: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 36: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 37: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 38: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Italy (2020-2034)
Figure 39: Total Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 40: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 41: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 42: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 43: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 44: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Spain (2020-2034)
Figure 45: Total Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 46: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 47: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 48: Severity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 49: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 50: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in the UK (2020-2034)
Figure 51: Total Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Figure 52: Age-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Figure 53: Gender-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Figure 54: Severity-specific Diagnosed Prevalent cases of Dermatomyositis in Japan (2020-2034)
Figure 55: Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Figure 56: Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis in Japan (2020-2034)
Figure 57: Patient Journey

Related Topics

Related Reports

Dermatomyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Dermatomyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 128 Pages
  • Global
From
Dermatomyositis - Pipeline Insight, 2024 - Product Image

Dermatomyositis - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Sarcopenia Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Sarcopenia Market Insight, Epidemiology and Market Forecast - 2032

  • Drug Pipelines
  • 136 Pages
  • Global
From
Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Osteoporosis: Epidemiology Forecast to 2033 - Product Image

Osteoporosis: Epidemiology Forecast to 2033

  • Report
  • 41 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.